|
Gene: SERPINE2 |
Gene summary for SERPINE2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SERPINE2 | Gene ID | 5270 |
Gene name | serpin family E member 2 | |
Gene Alias | GDN | |
Cytomap | 2q36.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R498 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5270 | SERPINE2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.89e-04 | 2.94e-01 | -0.1808 |
5270 | SERPINE2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.58e-13 | 5.40e-01 | -0.0811 |
5270 | SERPINE2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.48e-07 | 2.07e-01 | -0.1088 |
5270 | SERPINE2 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.61e-03 | 4.67e-01 | -0.2602 |
5270 | SERPINE2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.37e-03 | 1.25e-01 | -0.059 |
5270 | SERPINE2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 6.03e-04 | 1.89e-01 | 0.0588 |
5270 | SERPINE2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.22e-30 | 6.29e-01 | 0.3859 |
5270 | SERPINE2 | A001-C-207 | Human | Colorectum | FAP | 1.02e-05 | 3.09e-01 | 0.1278 |
5270 | SERPINE2 | CRC-1-8810 | Human | Colorectum | CRC | 5.82e-06 | 3.06e-01 | 0.6257 |
5270 | SERPINE2 | LZE2T | Human | Esophagus | ESCC | 1.68e-10 | 5.29e-01 | 0.082 |
5270 | SERPINE2 | LZE5T | Human | Esophagus | ESCC | 4.70e-02 | -8.23e-01 | 0.0514 |
5270 | SERPINE2 | LZE7T | Human | Esophagus | ESCC | 2.04e-09 | -8.85e-01 | 0.0667 |
5270 | SERPINE2 | LZE8T | Human | Esophagus | ESCC | 1.44e-12 | -7.96e-01 | 0.067 |
5270 | SERPINE2 | LZE20T | Human | Esophagus | ESCC | 5.23e-07 | -7.25e-01 | 0.0662 |
5270 | SERPINE2 | LZE22D1 | Human | Esophagus | HGIN | 3.80e-07 | -9.64e-01 | 0.0595 |
5270 | SERPINE2 | LZE22T | Human | Esophagus | ESCC | 4.33e-07 | -6.50e-01 | 0.068 |
5270 | SERPINE2 | LZE24T | Human | Esophagus | ESCC | 2.07e-02 | -5.24e-01 | 0.0596 |
5270 | SERPINE2 | LZE22D3 | Human | Esophagus | HGIN | 3.26e-05 | 9.35e-01 | 0.0653 |
5270 | SERPINE2 | P1T-E | Human | Esophagus | ESCC | 4.83e-07 | -9.64e-01 | 0.0875 |
5270 | SERPINE2 | P10T-E | Human | Esophagus | ESCC | 2.02e-03 | -2.30e-01 | 0.116 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
GO:0042177 | Colorectum | AD | negative regulation of protein catabolic process | 55/3918 | 121/18723 | 1.19e-09 | 8.85e-08 | 55 |
GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
GO:0034109 | Colorectum | AD | homotypic cell-cell adhesion | 40/3918 | 90/18723 | 4.37e-07 | 1.67e-05 | 40 |
GO:0042060 | Colorectum | AD | wound healing | 128/3918 | 422/18723 | 2.73e-06 | 7.89e-05 | 128 |
GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
GO:0052547 | Colorectum | AD | regulation of peptidase activity | 137/3918 | 461/18723 | 4.12e-06 | 1.12e-04 | 137 |
GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
GO:0045861 | Colorectum | AD | negative regulation of proteolysis | 106/3918 | 351/18723 | 2.33e-05 | 4.57e-04 | 106 |
GO:0002028 | Colorectum | AD | regulation of sodium ion transport | 36/3918 | 90/18723 | 2.89e-05 | 5.37e-04 | 36 |
GO:0052548 | Colorectum | AD | regulation of endopeptidase activity | 124/3918 | 432/18723 | 6.58e-05 | 1.07e-03 | 124 |
GO:0050878 | Colorectum | AD | regulation of body fluid levels | 108/3918 | 379/18723 | 2.54e-04 | 3.20e-03 | 108 |
GO:0010720 | Colorectum | AD | positive regulation of cell development | 87/3918 | 298/18723 | 4.17e-04 | 4.71e-03 | 87 |
GO:0070527 | Colorectum | AD | platelet aggregation | 26/3918 | 67/18723 | 6.20e-04 | 6.48e-03 | 26 |
GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
GO:0061458 | Colorectum | AD | reproductive system development | 116/3918 | 427/18723 | 1.11e-03 | 1.01e-02 | 116 |
GO:0048608 | Colorectum | AD | reproductive structure development | 114/3918 | 424/18723 | 1.78e-03 | 1.47e-02 | 114 |
GO:0050767 | Colorectum | AD | regulation of neurogenesis | 99/3918 | 364/18723 | 2.35e-03 | 1.82e-02 | 99 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SERPINE2 | SNV | Missense_Mutation | c.236N>A | p.Leu79Gln | p.L79Q | P07093 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
SERPINE2 | SNV | Missense_Mutation | c.101N>C | p.Phe34Ser | p.F34S | P07093 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-DD-A4NV-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
SERPINE2 | SNV | Missense_Mutation | novel | c.943N>C | p.Asp315His | p.D315H | P07093 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-3396-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | alimta | SD |
SERPINE2 | SNV | Missense_Mutation | novel | c.442T>C | p.Cys148Arg | p.C148R | P07093 | protein_coding | tolerated(0.25) | possibly_damaging(0.877) | TCGA-55-7907-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SERPINE2 | SNV | Missense_Mutation | c.1016T>C | p.Ile339Thr | p.I339T | P07093 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-55-8092-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SERPINE2 | SNV | Missense_Mutation | novel | c.897N>T | p.Lys299Asn | p.K299N | P07093 | protein_coding | tolerated(0.15) | probably_damaging(0.976) | TCGA-62-8399-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
SERPINE2 | SNV | Missense_Mutation | c.131N>A | p.Ser44Tyr | p.S44Y | P07093 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-69-7980-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SERPINE2 | SNV | Missense_Mutation | novel | c.394N>A | p.Ser132Thr | p.S132T | P07093 | protein_coding | deleterious(0.01) | benign(0.143) | TCGA-78-7146-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SERPINE2 | SNV | Missense_Mutation | c.457N>T | p.Val153Leu | p.V153L | P07093 | protein_coding | tolerated(0.37) | benign(0.003) | TCGA-78-7536-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
SERPINE2 | SNV | Missense_Mutation | c.368N>A | p.Ala123Asp | p.A123D | P07093 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |